Adamis Pharmaceuticals has entered into a licensing agreement with Allergan’s wholly owned subsidiary, Watson Laboratories, to commercialize Adamis’ Epinephrine Pre-filled Syringe (PFS) product candidate for the emergency treatment of anaphylaxis. Watson will obtain commercial rights for the U.S. in exchange for an upfront fee and potential regulatory and performance based milestone payments totaling up to $32.5 million. Additionally, Watson will pay double-digit royalties to Adamis based on ...